12:00 AM
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RM-131: Phase II started

Rhythm began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 10-100 µg subcutaneous RM-131 for 35 days in about 125 patients with Type I...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >